Pharma Focus Asia

Webinar Sponsored byYOKOGAWA


24th November 2020


11:30 AM (India)

02:00 PM (SGT)

03:00 PM (Japan)

Paul E. Cizdziel

Paul E. Cizdziel

Global Market Development, Life Innovation Business Headquarters

Yokogawa Electric Corporation

Integration of soft-sensor technologies with CHO-cell predictive models for improved bioreactor automation and process control.

Fed-batch mammalian cell culture in stirred-tank bioreactors for cell and biologic production is a standard bioprocess application. Probes and control systems are frequently used for monitoring and automating adjustments of parameters such as pH, gases and temperature. Although effective at stabilizing a healthy physical growth environment, sampling and off-line assays are still often required to monitor growth phase and media depletion effects for supplementation with vital nutrients.


By use of optical (spectroscopy) probes, media concentrations of key components (i.e. glucose and lactate) can be monitored in real-time. This data, when coupled with automated delivery, can drive the controlled supply of key nutrients throughout the cell culture timeline. Furthermore, impedance spectroscopy (based on electrical capacitance) can also be employed to detect cellular biomass accumulation. However, a critical and challenging issue with both of these soft-sensor technologies is the development of dynamic cell models (computer algorithms) to properly interpret the information in real-time for a specific bioproduction system. Furthermore, integration of all the essential probes, instruments, software and delivery systems can be a daunting task.

We have created a default control algorithm and next generation integrated system for CHO cell expression of biologics that can be customized in as little as three optimization runs. The protocol and tools lead to an optimized algorithm that precisely aligns the real-time sensor data with off-line biochemical assays uniquely matched to your CHO cell medium and expression system from early-stage to late-stage culture. This eliminates the need for repeated sample testing, and provides the means for real-time data to drive precision process control. By employing a proprietary self-learning predictive-control algorithm, continuous glucose adjustments are made, resulting in high cell counts, better viability, and improved biologic yield.

Yokogawa’s expertise in automation, sensors, control systems and engineering in various commercial applications are now being re-purposed and employed to bring better performance to biopharmaceutical production. The technology can speed process development and open new possibilities for control of biopharmaceutical production.

What participants will learn:

Webinar participants will learn about critical considerations in soft-sensor use that impede more widespread adoption of spectroscopic technologies for real-time process control, and how we have overcome these challenges. In addition, data will be shared demonstrating how calibration with off-line assays has been simplified using software tools to produce accurate cells models with minimal effort. And discussion about how dynamic predictive control for glucose feeding can affect bioreactor performance and biopharmaceutical integrity.

Who should attend (Targeted Profiles, Audiences):

  • Biopharmaceutical Process Development / Manager, Engineer, Scientist
  • Biopharmaceutical Upstream Manufacturing / Manager, Engineer, Scientist
  • Bioprocess Research / Manager, Engineer, Scientist
  • Bioprocess Business Development
  • Platform Technology manager / R&D, Bioprocess

" Professionals across the globe have already benefitted. Hurry Register Now! "

About - Paul E. Cizdziel

Paul has nearly three decades of experience in market-leading global life-science research supply companies including ThermoFisher, Merck Millipore, and REPROCELL in executive positions of technology management, business development, marketing and sales. He has also held scientific positions at the National Institute of Environmental Health Science (NC, USA) and the Yokohama RIKEN Institute. Currently Paul is employed with Yokogawa Electric Corporation (Tokyo) in global market development for commercialization of new biopharmaceutical engineering production technologies. Having worked in Japan for over 20 years, he is a permanent resident currently residing in Yokohama Japan with his wife and family.